Over the past two years, the Covid‑19 pandemic has been the most visible priority. However, other healthcare challenges in Latvia have not disappeared — and have likely become even more pressing. Thanks to the decision of lawmakers, significant funding has been allocated for the treatment of oncology patients in the coming years. Still, the oncology sector requires substantial additional investment to ensure that patient care reaches a quality level comparable to our neighboring countries, Lithuania and Estonia.
Unfortunately, Latvia continues to have an extremely high rate of premature mortality and significantly lower life expectancy compared to neighboring countries.
To improve this essential indicator of quality of life, systemic action is required.
The main causes of premature mortality are cardiovascular diseases that are not treated in time, as well as oncology and diabetes-related conditions. In the autumn, the government continues to discuss the public health guidelines for the coming years (2021–2027). Once the Cabinet of Ministers adopts them, this document will become the primary framework for national health policy. Then we will be able to assess which goals policymakers aim to achieve over the next seven years.
Working in the interests of our clients, we strive to ensure that the goals set out in policy documents are those that best reflect the needs of patients and that sufficient financial resources are allocated to achieve them.
